Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Burroughs Wellcome Retrovir

Executive Summary

Temporary distribution system, set up initially to ensure that the limited supply of AZT would reach target population of AIDS and advanced ARC patients, will be discontinued ahead of schedule. At the time of the drug's approval in March, Burroughs Wellcome said it would dissolve the elaborate distribution system once the company had enough drug to meet demand. Last spring, B-W predicted supply levels would not reach enough for 30,000 patients until year end; however, the company now says it can treat 50,000 patients.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS012466

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel